COPD — Pharmacologic Management (ATS 2020)

Personal study digest, pitched for IM boards / a rising pulmonary or IM subspecialty fellow. Scope: this ATS guideline covers only pharmacologic maintenance of STABLE COPD — six focused questions on inhalers, chronic oral steroids, and opioids for dyspnea. It does not cover diagnosis/spirometry, acute-exacerbation management, oxygen, or non-pharmacologic care; those live in the GOLD report, which is the day-to-day framework and is used below only in the currency layer. Recommendations carry the guideline’s GRADE strength and certainty. The “What’s changed since 2020” section is reviewer synthesis of newer evidence, each claim cited — not guideline text.

In one line

Dual bronchodilation (LABA/LAMA) is the backbone for symptomatic COPD; add an ICS only for the EXACERBATOR (or high eosinophils), and pull the ICS back off if a year passes without an exacerbation. The whole guideline is six answers built around that spine.

The six recommendations at a glance

Question a clinician faces	ATS answer	Strength · certainty
Symptomatic (dyspnea / exercise intolerance) — mono- or dual bronchodilator?	LABA/LAMA over LABA or LAMA monotherapy	Strong · moderate
Still symptomatic on LABA/LAMA — step up to triple?	Add ICS (→ ICS/LABA/LAMA) — but only if ≥1 exacerbation in the past year (needing antibiotics, oral steroids, or hospitalization)	Conditional · moderate
On triple therapy — can I stop the ICS?	Yes — withdraw the ICS if NO exacerbations in the past year	Conditional · moderate
Blood eosinophilia (≥2% or ≥150/µL) — add ICS?	No general recommendation — except add ICS if ≥1 exacerbation in the past year	Conditional · moderate
Severe, frequent exacerbations — chronic oral steroids?	Against maintenance oral corticosteroids	Conditional · low
Advanced refractory dyspnea despite optimal therapy?	Consider opioid-based therapy (shared decision-making)	Conditional · very low

Start here: the backbone (Q1)

LABA/LAMA beats either monotherapy for symptomatic patients — a strong recommendation on moderate certainty. Across 24 RCTs it cut exacerbations (RR 0.80) and hospital admissions (RR 0.89), with no excess adverse events. Symptom/QOL gains were statistically real but below the MCID.
Prefer a single combination inhaler over two separate devices — same drugs, less burden.

When to add the ICS — and when to pull it off (Q2–Q4)

The whole ICS decision turns on EXACERBATIONS, not symptoms. Step up to triple only if the patient exacerbates (≥1 in the past year needing antibiotics / oral steroids / hospitalization). In that group, triple cut exacerbations (rate ratio 0.71 overall; ~230 fewer per 1,000 in exacerbators) and the panel judged this to outweigh the 39% higher pneumonia rate (~15 more pneumonias per 1,000).
No exacerbation history? De-escalate. ICS can be withdrawn from triple therapy back to LABA/LAMA — no significant increase in exacerbations, pneumonia, or death; the QOL dip was below the MCID.
Eosinophilia alone is not an indication. ATS made no recommendation for eosinophilia by itself; it favors ICS only when eosinophilia coincides with an exacerbation history. (Contrast the current GOLD eosinophil thresholds below.)

What ATS says NO to, and the one palliative YES (Q5–Q6)

Against chronic maintenance oral corticosteroids even in severe, frequent exacerbators — no mortality or exacerbation benefit in RCTs, with a significant excess of adverse events (RR 1.65). This is the maintenance setting only; the short oral-steroid burst for an acute exacerbation is unaffected and remains standard.
Opioids for advanced refractory dyspnea — a conditional YES on very-low certainty. Dyspnea was the only outcome that crossed the MCID (SMD −0.60); no benefit in exercise capacity. A palliative measure inside shared decision-making, not disease-modifying.

Key decisions a fellow owns

Anchor the ICS decision on exacerbations — start it for exacerbators, stop it for non-exacerbators. Symptoms drive bronchodilators; exacerbations drive the ICS.
Weigh the pneumonia trade-off before triple therapy — real but outweighed by exacerbation reduction in the right (exacerbating) patient.
Reassess ICS at least yearly — a year without an exacerbation is the cue to consider withdrawal, checking blood eosinophils first (see currency layer).
Remember what actually moves mortality — smoking cessation and (in hypoxemia) long-term oxygen; note the newer triple-therapy mortality signal below.

What’s changed since 2020

Reviewer synthesis placing this pharmacologic guideline in today’s evidence — each claim cited. Not guideline text. Trials/approvals postdating the guideline’s July 2019 evidence cutoff were PubMed/web-verified this run.

Triple therapy now carries an all-cause MORTALITY signal. IMPACT — FF/UMEC/VI reduced all-cause mortality vs LABA/LAMA Am J Respir Crit Care Med 2020; 10.1164/rccm.201911-2207OC — and ETHOS — 320-µg-budesonide triple reduced exacerbations (rate ratio 0.76 vs LABA/LAMA) with a concordant mortality reduction NEJM 2020; 10.1056/NEJMoa1916046. Both postdate the guideline and directly qualify its conclusion that “only smoking cessation” improves survival. Caveat: mortality was a secondary endpoint, seen vs the non-ICS dual, and attributed to the ICS component.
GOLD reorganized the treatment algorithm to ABE (2023, current through 2025). Groups A, B, and E (“E” = exacerbators: ≥2 moderate or ≥1 hospitalization/yr) replaced the old ABCD; initial therapy for E is LABA+LAMA, adding ICS when eosinophils are high. The ATS guideline is organized by PICO question, not by group.
Eosinophil thresholds sharpened to <100 / ≥300. GOLD now uses <100 cells/µL to argue against ICS and ≥300 to favor it (100–<300 intermediate) — finer than ATS 2020’s ≥2% or ≥150. The ≥300 threshold also now gates biologic eligibility.
First biologic approved for COPD — dupilumab. Anti-IL-4Rα/IL-13; FDA-approved Sept 2024 as add-on maintenance for the eosinophilic phenotype (eos ≥300) on triple therapy. BOREAS NEJM 2023; 10.1056/NEJMoa2303951 and NOTUS NEJM 2024; 10.1056/NEJMoa2401304 cut exacerbations ~30% (rate ratio 0.70 / 0.66). Entirely postdates the guideline.
New inhaled class — ensifentrine (Ohtuvayre). A dual PDE3/PDE4 inhibitor, FDA-approved June 2024; ENHANCE-1/-2 improved lung function and reduced exacerbations Am J Respir Crit Care Med 2023; 10.1164/rccm.202306-0944OC. First novel inhaled mechanism for COPD maintenance in >20 years.
Still current. The LABA/LAMA-over-monotherapy backbone, triple-for-exacerbators, ICS-withdrawal-if-no-exacerbations, avoid chronic oral steroids, and opioids for refractory dyspnea all remain aligned with GOLD 2023–2025.

Recency-sensitive — confirm before quoting as current

Dupilumab (Sept 2024) and ensifentrine (June 2024) FDA approvals, and the GOLD ABE / <100–≥300 eosinophil framework, postdate my training cutoff — all web/PubMed-verified this run; confirm against the current GOLD report before quoting.
The triple-therapy mortality claim rests on secondary endpoints (IMPACT, ETHOS) vs LABA/LAMA — present it as a signal, not a primary-endpoint mortality trial.

Anki cards minted this run (4)

Triple therapy reduces all-cause mortality vs LABA/LAMA (IMPACT, ETHOS) — the currency update to “only smoking cessation + O₂ lower COPD mortality.”
ICS withdrawal from triple therapy is reasonable if no exacerbations in the past year (WISDOM).
Opioids for advanced refractory dyspnea (the one ATS symptom benefit exceeding the MCID).
ATS recommends against chronic maintenance oral corticosteroids (harm without benefit; distinct from the acute burst).

Held as duplicates (already in the deck): the eosinophil ICS thresholds (<100 / ≥300), dupilumab for eosinophilic COPD (BOREAS/NOTUS), and ensifentrine (inhaled PDE3/4). Flagged for reconciliation: an existing card states only smoking cessation + O₂ lower COPD mortality — now partially superseded by the triple-therapy signal (card 1 complements it).

Sources

1. Nici L, Aaron SD, et al. Pharmacologic Management of COPD: An Official ATS Clinical Practice Guideline. Am J Respir Crit Care Med 2020;201(9):e56–e69. DOI 10.1164/rccm.202003-0625ST; PMID 32283960. — local verbatim capture (source of record).
2. Lipson DA, et al. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in COPD (IMPACT). Am J Respir Crit Care Med 2020;201(12):1508–1516. DOI 10.1164/rccm.201911-2207OC.
3. Rabe KF, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD (ETHOS). N Engl J Med 2020;383:35–48. DOI 10.1056/NEJMoa1916046.
4. Bhatt SP, et al. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS). N Engl J Med 2023;389:205–214. DOI 10.1056/NEJMoa2303951.
5. Bhatt SP, et al. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation (NOTUS). N Engl J Med 2024;390(24):2274–2283. DOI 10.1056/NEJMoa2401304.
6. Anzueto A, et al. Ensifentrine, a Novel PDE3/PDE4 Inhibitor for COPD (ENHANCE-1 and ENHANCE-2). Am J Respir Crit Care Med 2023;208(4):406–416. DOI 10.1164/rccm.202306-0944OC.
7. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of COPD — 2025 Report. goldcopd.org (ABE groups; blood-eosinophil ICS thresholds <100 / ≥300). FDA approvals: dupilumab (Sept 2024), ensifentrine (June 2024).